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Background. The mechanism of action of artemisinins against malaria is unclear, despite their widespread use
in combination therapies and the emergence of resistance.
Results. Here, we report expression of PfATP6 (a SERCA pump) in yeast and demonstrate its inhibition by arte-
misinins. Mutations in PfATP6 identiﬁed in ﬁeld isolates (such as S769N) and in laboratory clones (such as L263E)
decrease susceptibility to artemisinins, whereas they increase susceptibility to unrelated inhibitors such as cyclopia-
zonic acid. As predicted from the yeast model, Plasmodium falciparum with the L263E mutation is also more sus-
ceptible to cyclopiazonic acid. An inability to knockout parasite SERCA pumps provides genetic evidence that they
are essential in asexual stages of development. Thaperoxides are a new class of potent antimalarial designed to act
by inhibiting PfATP6. Results in yeast conﬁrm this inhibition.
Conclusions. The identiﬁcation of inhibitors effective against mutated PfATP6 suggests ways in which artemisi-
nin resistance may be overcome.
Keywords. Artemisinins; PfATP6; yeast; malaria; Plasmodium falciparum; drug resistance; thaperoxides; cyclo-
piazonic acid; desferioxamine.
Schatzmann’s observation that cardiac glycosides in-
hibited active exchange of Na+ and K+ across red cell
membranes was critical to the discovery of Na+/K+
ATPase as their target [1]. Subsequently, activated
benzimidazoles were found to inhibit parietal cell H+/
K+ ATPases [2], thereby providing effective treatments
for inappropriately elevated gastric acid. These studies
established the value of P-type ATPases as targets for
distinct chemical classes used to treat a variety of unre-
lated diseases. Artemisinins are key components of most
commonly used antimalarial combination therapies.
They were hypothesized to act by inhibiting a parasite-
encoded P-Type Ca2+ ATPase (PfATP6) of the SERCA
family [3]. Consistent with this suggestion, PfATP6 was
inhibited after expression in Xenopus laevis oocytes.
Mutations in PfATP6 (eg, L263E) were predicted and
then found to decrease sensitivity to artemisinins in this
assay [4], in which approximately 1% of membrane-
associated protein may be PfATP6 [5]. Amino acid
polymorphisms at other positions in PfATP6 were sub-
sequently associated with decreased susceptibility of
ﬁeld parasites to artemisinins (reviewed in [6–8]).
However, introducing mutations in PfATP6 into
cloned parasite lines generates phenotypes that vary in
sensitivity to artemisinins [9, 10]. Also, highly puriﬁed
PfATP6 reconstituted in artiﬁcial membranes is not in-
hibited by artemisinins and only poorly by thapsigar-
gin, a speciﬁc SERCA inhibitor [11] that is predicted in
modeling studies to inhibit PfATP6 [12]. To resolve
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these discrepancies, we developed a whole cell yeast expression
system to study PfATP6. This model conveniently allows as-
sessments of how polymorphisms in PfATP6 in ﬁeld isolates
relate to the emerging problem of artemisinin resistance. It also
clariﬁes mechanisms of antiparasitic action of this class of drug.
Results associate polymorphisms in PfATP6 linked to arte-
misinin resistance in vitro in French Guiana and Sénégal [13]
with decreased sensitivity to artemisinins of yeast-expressed
PfATP6 sequences. They also independently validate PfATP6
as a drug target by genetic experiments and identify new inhibi-
tors as leads for antimalarials.
RESULTS
Genetic Studies of PfATP6
Genetic validation of PfATP6 as a drug target has not been
reported to our knowledge. We carried out knockout (KO)/
complementation experiments in the reference line 3D7 with a
single crossover homologous recombination strategy (Figure 1A),
as with the glucose transporter, PfHT [14]. Two attempts were
unsuccessful, including complementation with wild-type or
double mutated full length pfatp6 (Figure 1C) and tagging the
3′ end of the gene with green ﬂuorescent protein (GFP), myc,
or double HA epitopes (Figure 1B). In all cases, blasticidin-
resistant parasites were obtained with episomes. Similarly, a
double recombination construct failed to KO pbserca in the
more tractable Plasmodium berghei system, and C-terminal
tagging was also unsuccessful (data not shown). Thus, pfatp6 is
accessible for crossovers introducing single mutations, support-
ing the idea that it cannot be knocked out [9, 10] or tagged at
the C-terminus. We developed an alternative expression system
to study the function of PfATP6 and mutations including those
in ﬁeld isolates.
Yeast Expression
To avoid extensive puriﬁcation and reconstitution after expres-
sion in yeast [11] or laborious assays of membrane preparations
of Xenopus oocytes [3], we adapted a yeast functional assay
used to express several exogenous eukaryotic Ca2+ ATPases [15].
This assay has the advantage of assessing drug action in intact
cells. The host strain (K667) lacks one of its 2 Ca2+ ATPase
genes PMC1, whereas the other gene, PMR1, is inactive as calci-
neurin is also missing. A codon-optimized version of pfatp6
was required for yeast expression [11].
PfATP6 was localized to cytosolic structures in yeast
(Figure 2A, upper panel) with a similar pattern in parasites
(Figure 2A, lower panel) that is consistent with distribution of
endoplasmic reticulum (ER). To verify this localization, PfATP6
was compared in ER-enriched microsomal membranes and
Figure 1. Strategy for knockout (KO), complementation and tagging of pfatp6 gene in Plasmodium falciparum 3D7. A, Single cross-over homologous
recombination of the KO (pCAM-BSD KOA6) plasmid and the endogenous gene (WT locus) should result in 2 truncated nonfunctional copies of the gene
(recombinant locus). B, Tagging of the 3′ end of PfATP6 locus with green ﬂuorescent protein (GFP), double HA or cmyc tags. Wild-type (WT) and recombi-
nant loci are shown. Arrows indicate the location of polymerase chain reaction (PCR) primers. C, Complementation constructs, carrying WT and mutated
PfATP6 (pCHD-A6) would allow PfATP6 expression under the Pfhsp86 promoter. Complementation of KO parasites without a tagged pfatp6 construct was
not successful, and neither was episomal expression only of PfATP6.
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whole cell extracts from yeast by Western analysis (Figure 2B).
Endogenous yeast non-SERCA P type Ca2+ ATPases (Pmr1p
and Pmc1p) in reference strain BY4741 are not detected by
anti-PfATP6 anti-peptide polyclonal reagent (Figure 2B, lane
a). PfATP6 is detected in membrane extracts from both trans-
genic yeast and parasites (P. falciparum 3D7; Figure 2B, lane b
and right panel).
Yeast Assays
To conﬁrm function, we ﬁrst established conditions for yeast
growth that depend on rescue by PfATP6. A reference strain
(BY4741) with 2 Ca2+ ATPases can grow on solid (YPD) me-
dium supplemented with CaCl2 (0–100 mM, Figure 3A, upper
row). As expected, strain K667 cannot grow when stressed with
ambient calcium concentrations >25 mM (Figure 3A, 2nd row),
and the addition of an empty vector (K667::pUGpd; Figure 3A,
3rd row) does not alter this calcium sensitivity. Growth of K667 is
restored toward that of the reference strain by expressing PfATP6,
albeit not to wild-type levels (K667::pfatp6; Figure 3A, last row).
Liquid cultures allow quantitation of growth and show that
PfATP6 expressing yeast (OD620 nm) grow signiﬁcantly better
in media supplemented with ≥50 mM CaCl2 compared with
yeast strains (K667 and K667::pUGpd) without Ca2+ ATPases
(Figure 3B; P < .001). PfATP6 cannot restore growth in increas-
ing manganese concentrations, conﬁrming that (as with recon-
stituted protein [11]) it acts speciﬁcally as a Ca2+ ATPase. This
manganese sensitivity also conﬁrms that the Ca2+/Mn2+
ATPase PMR1 is inactive in K667 (Figure 3C). Growth curves
for yeast in different calcium concentrations were used to select
42 hours as the time point for assessing effects of drugs (Sup-
plementary Figure 1). This allows discrimination of growth
rates at the plateau phase (see Methods). The mean ± standard
deviation (SD) interassay coefﬁcient of variation (CV) for
pUGpd was 1.85% ± 0.017% (calculated as an overall mean
(n = 28) using the mean CV of 3 biological replicates after
assays with artemisinins and cyclopiazonic acid [CPA] at all re-
ported concentrations) and for K667::pfatp6 was 6.65% ± 0.07%
(calculated as for pUGpd with 40 mM CaCl2 in medium, and
including assays for chloroquine and thapsigargin (n = 36)).
BY4741 growth without calcium is inhibited by artemisinins
perhaps by inhibition of yeast mitochondrial function [16] and
through effects on its own Ca2+ ATPases [17]. Strain K667 can
Figure 2. PfATP6 in yeast and parasites. A, Upper panel: Indirect immunoﬂuorescence with anti-PfATP6 polyclonal antibody on Saccharomyces cerevi-
siae K667::pfatp6 conﬁrms expression in cytosolic structures (green) with nuclei stained with DAPI (blue). Lower panel: A similar distribution is apparent in
asexual stage parasites (large trophozoites of Plasmodium falciparum strain 3D7). B, Upper panel: Western blot of total protein extract of yeast (10 µg, left)
and parasites (10 µg, right). Reference strain BY4741 (lane a) is a negative control, whereas K667::pfatp6 shows a band of predicted mass (upper arrow). A
similar band is detected on parasite extracts (3D7). Lower panel: Reference yeast strain (BY4741, 10 µg lane a) and K667::pfatp6 were used to make ER-
enriched preparations (Methods) and assayed with anti-PfATP6 antibody. Only K667::pfatp6 (10 µg lane b) shows PfATP6.
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only be grown without calcium, so artemisinins can still inhibit
growth by acting on mitochondria but not on yeast Ca2+
ATPases. We therefore used 40 mM CaCl2, in liquid cultures to
screen artemisinins for their ability to inhibit rescue of K667 by
PfATP6. These conditions do not permit K667 to grow without
PfATP6, allowing the conclusion that inhibition is of PfATP6′s
ability to rescue yeast. All artemisinins inhibited yeast growth
signiﬁcantly (Figure 4A, P < .001).
CPA inhibits SERCAs at a different binding site from thapsi-
gargin [18] (where we hypothesized that artemisinins may act),
and signiﬁcant inhibition is also observed with CPA (Figure 4A).
Several experiments conﬁrmed the speciﬁcity of these inhibi-
tors. Growth of K667 is not inhibited by dimethyl sulfoxide
solvent (1% maximum, not shown) and CPA (up to 100 µM,
Figure 4B) did not inhibit any strain without PfATP6 (BY4741,
K667, K667::pUGpd).
Table 1A includes results with different concentrations of in-
hibitors of K667::pfatp6. 2-deoxy artemisinin lacks an endoper-
oxide bridge and is therefore inactive as an antimalarial and
interestingly does not inhibit growth. Chloroquine, an antima-
larial that acts in the parasite’s food vacuole, also does not
inhibit K667::pfatp6. As is conventional, we are careful not to
translate concentrations that inhibit K667::pfatp6 to those re-
quired to kill parasites. Higher concentrations of ATPase inhib-
itors are needed to inhibit yeast growth compared with
potencies in biochemical assays [18].
Results from K667::pUGpd (vector control) are not directly
comparable to those with K667::pfatp6, as the former have been
grown without supplementary calcium. Supplementary Table 1A
presents the effects of inhibitors on pUGpd, representing inhi-
bition that is not dependent on PfATP6. Most inhibitors have
little or no effect. Thapsigargin and CPA inhibit growth in
K667::pfatp6 but not in K667::pUGpd, consistent with a specif-
ic interaction with PfATP6 (Table 1A and Supplementary
Table 1A). Some artemisinins inhibit K667::pUGpd at higher
concentrations (for example, artemisone (100 µM) inhibits by
approximately 25%) but all Ca2+ ATPase inhibitors (including
artemisinins) inhibit K667::pfatp6 signiﬁcantly more.
Figure 3. Functional assay of PfATP6 in growing yeast. A, Saturated liquid cultures of yeast cells were diluted (as indicated by OD600 values) and
spotted onto yeast peptone dextrose (YPD) plates supplemented with 25, 50, or 100 mM CaCl2. BY4741 (upper row) tolerates all calcium concentrations
whereas K667 and K667::pUGpd (bearing empty vector; middle rows) cannot grow in calcium ≥50 mM. PfATP6 (K667::pfatp6) restores growth in higher
ambient calcium (lower row). B, K667 (bars), K667::pUGpd (red bars) and K667::pfatp6 (blue bars) were diluted to a cell density of 0.5 and inoculated into
YPD medium containing CaCl2 at indicated concentrations. Yeast cell density was determined after growth at 30°C for 18 h. Data are mean ± SEM values
of at least 9 replicates (3 independent biological experiments). PfATP6 rescue increases growth of K667 signiﬁcantly (***P < .0001). C, K667 (bars), K667::
pUGpd (blue bars), and K667::pfatp6 (red bars) were diluted to a cell density of 0.5 and inoculated into YPD medium containing MnSO4 at indicated concen-
trations. Data are mean ± SEM values of at least 9 replicates (3 independent biological experiments). There are no signiﬁcant differences between groups
(P > .05).
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To conﬁrm that mitochondrial inhibition by artemisinins is
not relevant to inhibition of K667::pfatp6, we assessed the
effects of adding deferoxamine (DFO). Previously, the artemisi-
nin susceptibility of yeast mitochondria was antagonized by
DFO [16]. In contrast, DFO increased the inhibition of yeast
growth by artemisinin (10 µM, Supplementary Table 1B) and
had no effect on actions of artemether or artemisone. At the
highest concentrations of artesunate there was some antago-
nism with DFO.
Mutations in PfATP6
Next we tested how mutations in PfATP6 inﬂuence artemisinin
activity. These assays (in extracellular calcium between 10 and
30 mM) examined mutations (L263E, A623E, S769N A623E/
S769N) by comparing results with wild-type PfATP6 and
vector only controls (Figure 5A, lower panel).
All pfatp6 constructs rescued K667 growth in 10- and 20-
mM calcium, although S769N and A623E/S769N mutants were
signiﬁcantly less efﬁcient in 20-mM calcium. In 30-mM
calcium, all mutants of PfATP6 failed to rescue yeast in contrast
to wild-type PfATP6 (Figure 5A, lower panel). Western analysis
conﬁrmed expression of mutant PfATP6 proteins (Figure 5A,
upper panel). Mutations in PfATP6 reduce the efﬁciency of
yeast rescue, presumably by interfering with function. We then
tested sensitivity of mutant PfATP6 sequences to artemisinins
and compared them with wild-type PfATP6 (Table 1B and
Supplementary Table 2 for 95% conﬁdence intervals [CIs] of
mean differences between groups). S769N attenuated artemisi-
nins’ inhibition (except for artesunate 1 µM and artemisone
100 µM). For a double mutant (PfATP6 A623E/S769N) there
was also signiﬁcant attenuation of inhibition by all artemisinins
(10 µM). In contrast, higher concentrations of artemisone (100
µM) [19] produced even greater inhibition on all mutants. The
A623E mutant had less marked effects, failing to attenuate arte-
sunate’s inhibition.
In Xenopus oocyte membrane preparations, there was abolition
of sensitivity of PfATP6 to artemisinins [4]. We conﬁrmed in
yeast that L263E PfATP6 signiﬁcantly reduces but does
not abolish sensitivity to all artemisinins (Table 1B), perhaps re-
ﬂecting differences in 3 amino acid residues in PfATP6 sequence
expressed in Xenopus compared with the wild-type (3D7)
PfATP6 sequence expressed in yeast (sequence differences
Figure 4. Sensitivity of K667 with and without rescue by PfATP6 to artemisinins and cyclopiazonic acid. A, Inhibition of K667::pUGpd (blue bars) and
K667::pfatp6 (red bars) by different antimalarials expressed as percentage of control cultures (growth of each strain in absence of the drug). Yeast strains
were diluted to a cell density of 0.1 and inoculated into YPD medium (with 40 mM CaCl2 for experiments with K667::pfatp6) and 10 µM of drug as indicat-
ed. Yeast cell density was determined after growth at 30°C for 42 h (plateau phase, Supplementary Figure 4). Data are mean ± SEM values of at least 9
replicates (3 independent biological experiments) with signiﬁcant differences between growth of yeast without PfATP6 and supplementary Ca2+ and yeast
with PfATP6 and supplementary Ca2+ (***P < .001). B, CPA does not inhibit growth of yeast strains not expressing PfATP6 (BY4741, K667 and K667::
pUGpd). Yeast strains were diluted to a cell density of 0.1 and inoculated into YPD medium containing various concentration of drug as indicated (bars, no
drug, light green, 1 µM, medium green, 10 µM, dark green, 100 µM). CPA structure is reported. Abbreviations: AM, artemether; ART, artemisinin; AS,
artesunate; ATS, artemisone; CPA, cyclopiazonic acid; DHA, dihydroartemisinin.
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Table 1. Sensitivity of K667 Expressing Wild Type and Mutated PfATP6 to Antimalarials
(µM)
Growth (% control)
PfATP6
(A) artemisinin
1 100.2 ± 1.1
10 87.3 ± 1.2*
100 76.4 ± 1.2*
artesunate
1 90.1 ± 0.8
10 82.8 ± 1.3*
100 72.6 ± 0.8*
artemether
1 94.1 ± 2.7
10 80.7 ± 3.0**
100 77.1 ± 2.8**
artemisone
1 90.0 ± 0.3*
10 80.2 ± 0.9*
100 56.3 ± 1.2*
DHA
1 80.9 ± 0.9*
10 69.1 ± 1.4*
100 65.8 ± 3.0*
CPA
1 79.5 ± 6.7**
10 31.7 ± 2.4**
100 24.0 ± 1.7**
thapsigargin
1 100.5 ± 0.5
10 99.5 ± 0.6
100 86.9 ± 0.8*
chloroquine
1 101.6 ± 1.4
10 102.3 ± 1.0
100 100.4 ± 1.2
2de-QHS
1 100.9 ± 1.4
10 103.0 ± 1.5
100 98.1 ± 0.9
(µM) PfATP6 wt A623E/S769N A623E S769N L263E
(B) artemisinin
1 101.9 ± 1.0 104.7 ± 1.2 104.3 ± 1.7 105.3 ± 1.7 104.4 ± 2.1
10 91.7 ± 0.6 101.7 ± 1.1*** 100.5 ± 1.6*** 105.3 ± 1.8*** 104.5 ± 1.9***
100 71.8 ± 2.9 91.8 ± 0.5*** 73.6 ± 1.8 82.9 ± 0.5**** 75.4 ± 2.2
artesunate
1 96.6 ± 0.6 97.9 ± 2.0 96.6 ± 0.9 91.9 ± 1.1#### 98.8 ± 0.9
10 85.1 ± 0.9 91.1 ± 1.1*** 86.9 ± 0.6 87.8 ± 1.1 89.0 ± 0.6****
100 70.5 ± 2.3 85.4 ± 0.9*** 70.2 ± 2.4 78.5 ± 0.8**** 72.2 ± 2.2
artemether
1 100.1 ± 0.6 104.1 ± 1.5***** 100.0 ± 1.1 100.9 ± 1.5 103.5 ± 1.4*****
10 87.9 ± 1.5 95.7 ± 1.8**** 99.7 ± 1.6*** 103.0 ± 1.2*** 104.2 ± 1.3***
100 65.7 ± 2.4 59.0 ± 4.1 64.6 ± 1.4 74.8 ± 1.6**** 69.3 ± 2.4
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between PfATP6 in oocytes and the 3D7 sequence can be com-
pared with accession numbers PF3D7_0106300 and the original
sequence in [3]). Results (Table 1B) suggest that >1 mutation in
PfATP6 may synergize to reduce sensitivity to artemisinins.
It is striking that despite reduced capacity of mutant PfATP6
sequences to rescue yeast grown in calcium, they show de-
creased rather than increased sensitivity to artemisinins. To
conﬁrm this effect is speciﬁc for artemisinins, we tested sensi-
tivity of mutants to CPA and found it was increased (Figure 5B)
compared with wild-type PfATP6. We then examined parasites
with the L263E mutation to determine if they had increased
sensitivity to CPA, as predicted by results in yeast. Figure 5C
demonstrates that the IC50 for CPA approximately halved,
compared with an isogenic control (mean ± SEM for L263 =
10.3 ± 2.7 compared with 263E = 4.7 ± 1.1 µM; n = 5 P = .011).
There was no change in sensitivity to chloroquine (0.12 ± 0.01
compared with 0.14 ± 0.01 µM respectively).
New Chemical Classes
Figure 6A shows how a new chemical class introducing an en-
doperoxide bridge into the sesquiterpene scaffold of thapsigargin
(guaianolide-endoperoxides [12]) inhibits K667::pfatp6 without
inhibiting control yeast strains (eg, growth of strain BY4741
with or without calcium supplementation (Figure 6B)).
DISCUSSION
Whole cell expression in yeast provides new insights into
PfATP6 as a drug target as well as a screening tool for discovery
of inhibitors. Results conﬁrm ﬁndings from Xenopus oocytes
that all endoperoxides tested inhibit PfATP6 [3]. Yeast assays
have also elucidated functions of a Schistosoma mansoni Ca2+
ATPase [20], a Fasciola hepatica plasma membrane Ca2+
ATPase and mammalian SERCA1a. SERCA1a is sensitive to
thapsigargin [18] as well as to artemisinin [21], suggesting that
experiments with puriﬁed and relipidated PfATP6 may compro-
mise assessment of different inhibitor classes [11, 22]. Reconstitu-
tion may not achieve full physiological functionality as PfATP6
operates at one third the rate of mammalian SERCA [11].
Confounding by off-target effects of artemisinins in this
yeast model [16] has been minimized because assays have been
designed to rely on function of PfATP6, by selecting fermenta-
tive conditions when mitochondria are metabolically inactive.
Also, the lack of antagonism (and sometimes synergism) by
DFO of artemisinin inhibition of PfATP6 contrasts with an-
tagonism in yeast in nonfermentative conditions [16] when
artemisinins cause mitochondrial depolarization. Transgenic
parasites that no longer rely on mitochondria for asexual stage sur-
vival do not show increased resistance to artemisinins, as would
be predicted if mitochondria were important targets in vivo [23].
Artemisinins also inhibit the SERCAs of Toxoplasma [24, 25] and
cancer cell lines in membrane preparations [26] supporting results
from PfATP6 [3]. Alternative hypotheses for mechanisms of
action of artemisinins continue to be investigated to increase un-
derstanding of this important class of drug [8].
In modeling studies, thapsigargin, artemisinins, and thaper-
oxide [4, 12, 27, 28] may share a common binding site in
PfATP6 different from that which binds CPA [29]. Inhibition
Table 1 continued.
(µM)
Growth (% control)
PfATP6
artemisone
1 91.9 ± 0.7 100.3 ± 0.6*** 98.4 ± 1.7**** 96.4 ± 1.8***** 101.0 ± 2.0***
10 83.1 ± 0.7 96.5 ± 1.8*** 86.9 ± 1.2***** 91.9 ± 1.3*** 89.6 ± 1.7****
100 45.2 ± 4.2 56.1 ± 1.9 34.5 ± 2.2##### 30.9 ± 1.7#### 34.0 ± 2.8#####
DHA
1 90.7 ± 0.7 92.0 ± 1.7 94.9 ± 0.9**** 91.8 ± 2.1 95.8 ± 1.1****
10 82.7 ± 0.6 88.5 ± 1.7**** 82.2 ± 1.1 82.1 ± 2.3 80.1 ± 1.1
100 61.7 ± 3.0 72.6 ± 2.7***** 63.9 ± 3.1 60.7 ± 6.5 62.8 ± 3.4
(A) Sensitivity of K667 expressing PfATP6 to antimalarials. Results (mean±SEM) are expressed as percentage of control (growth in absence of drug). Data are the
mean of at least 9 replicates in 3 independent experiments. Growth in presence of drug was compared to growth without drug (in 40 mM CaCl2) with ANOVA. (B)
Sensitivity of K667 expressing PfATP6 (wild-type or mutated, as shown) to artemisinin derivatives. Growth is described as percentage of control (growth in YPD
medium supplemented with 20 mM CaCl2) Data are mean ± SEM values of at least 9 replicates (3 independent experiments). Student t test was used to compare
growth of mutated PfATP6 to wild-type. (Supplementary Table 2 summarizes 95% CAs of mean difference.) *indicates decreased sensitivity when compared to
PfATP6 wild-type, whereas # indicates increased sensitivity.
Abbreviations: CPA, cyclopiazonic acid; DHA, dihydroartemisinin.
* P < .0001.
** P < .0005.
*** P < .0009.
**** P < .0061.
***** P < .0385.
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by CPA of PfATP6 is demonstrable in 3 systems [3]: after ex-
pression in membranes of Xenopus oocytes, in yeast assays (this
study), and after reconstitution [11]. When CPA inhibition is
assayed with the L263E mutation in PfATP6, a compromise in
function in yeast increases sensitivity. This is paralleled by in-
creased sensitivity of parasites with the L263E mutation, pro-
viding an estimate of the degree of functional compromise
(halving of IC50 values) caused by such mutations for CPA.
This may explain why transfection of P. falciparum with
mutated PfATP6, or why ﬁeld isolates with mutations, yield
variable results for susceptibility to artemisinins. Mutations in
PfATP6 reduce sensitivity to artemisinins, but because PfATP6
function is compromised, this may not translate to large in-
creases in IC50. A “corrected” IC50 value for artemisinins may
be obtainable by normalizing results with simultaneous IC50
values for CPA.
The L263E mutation may also show less artemisinin resistance
in parasites than in oocytes because sequences assayed in oocytes
and parasites were not identical and also because of differences
between whole cell assays (parasites or yeast) and in Xenopus
membrane preparations. In parasites, other transport proteins
such as PfMDR1 may modulate the artemisinin resistance phe-
notype [9, 30]. The proposed ﬁtness cost of mutations in PfATP6
may then cause parasites to be outgrown in culture when
adapted from patients [31]. Linking mutations in PfATP6 in ﬁeld
isolates to artemisinin resistance could then depend on genetic
background, including compensatory mutations in proteins in-
volved in calcium homeostasis. Background is critical to assessing
the impact of other resistance genes such as pfcrt [32, 33].
The yeast model may therefore allow rapid assessment of
functional consequences of mutations in PfATP6, by eliminat-
ing variables in parasite assays and overcoming the difﬁculty of
establishing long-term cultures in parasites harboring pfatp6
ﬁeld mutations. These mutations may modify the propensity of
peroxides to cleave SERCAs through several mechanisms [34].
The increased susceptibility of mutant PfATP6 to CPA (Figure 5),
Figure 5. Effect of mutations in K667::pfatp6 and susceptibility of mutated P. falciparum to chloroquine and cyclopiazonic acid. A, Upper panel: Western
blot of total yeast protein. Anti-PfATP6 polyclonal antibody does not detect a band from yeast without PfATP6 (K667::pUGpd), whereas K667::pfatp6 and
mutants express protein. Growth of K667 (assayed as in Figure 3) with vector only or PfATP6 sequences was examined at different concentrations of
calcium in yeast peptone dextrose (YPD) and expressed as a percentage of control values after growth without calcium. Data are mean ± SEM values (at
least 9 replicates and 3 independent experiments). S769N PfATP6 and A623E/S769N PfATP6 impair growth rescue of yeast in higher Ca2+ (≥20 mM) con-
centrations (PfATP6 vs A623E/S769N **P = .0079 PfATP6 vs S769N **P = .0024; Student t test). Ten outliers identiﬁed by Grubbs test were removed from a
total of 504 replicates. B, Sensitivity of K667::pfatp6 wild-type (dark gray bars) and pfatp6 mutants (light-gray bars) to CPA (in 20 mM CaCl2). Yeast were
assayed and analyzed as in 4a with indicated concentrations of CPA. Inhibition by CPA of PfATP6 wild-type and individual mutants *** P < .0001. C, IC50
values for chloroquine (CQ) and CPA were estimated with [3H]hypoxanthine uptake in growth assays using synchronized ring-stage cultures of Plasmodium
falciparum (L263 7G8 and L263E 7G8). Growth was measured at 48 h as described by Desjardin et al [50] IC50s ± SEM are the mean of 5 independent ex-
periments (L263 CQ, green dots, L263E CQ, pink dots, L263 CPA, blue dots, and L263E CPA, red dots).
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in contrast to artemisinins encourages pursuit of CPA deriva-
tives as new leads.
A novel thaperoxide class of antimalarials was developed to
test the hypothesis that PfATP6 is targeted by artemisinins. In-
troduction of a peroxide bridge into the sesquiterpene heart of
thapsigargin increases antimalarial potency of thapsigargin by
approximately 100-fold. The most potent derivative (thaperox-
ide 22) also inhibits K667::pfatp6, conﬁrming that it remains
on target and providing assays for lead optimization (Figure 6).
Modeling studies of thaperoxides with PfATP6 and mutants
provide testable predictions [35].
Genetic validation of PfATP6 as a drug target should stimu-
late this further and has been attempted using KO and comple-
mentation methods, twice in 2 species of Plasmodium (as with
PfHT [14]), suggesting that SERCA function is essential for
blood stages of infection. Tagging the 3′ end of pfatp6 and
pbserca has not been possible despite accessibility of pfatp6 for
single site recombination experiments (Figure 1) [10].
Resistance to artemisinins can be deﬁned as for other classes
of antimalarial by a decrease in susceptibility of cultured para-
sites to one or more derivatives. As resistance increases, it may
increase treatment failures of some artemisinin combination
therapies. The magnitude of increase in resistance in vitro that
is associated with treatment failures in vivo has not been
deﬁned [36] although it is noteworthy that some parasites with
S769N PfATP6 have IC50 values >100 nM for artemether [13,
37]. A requirement for compensatory mutations may have
limited the spread of resistance associated with polymorphisms
in PfATP6 at present.
An in vivo deﬁnition of artesunate resistance that manifests
itself in prolonged parasite clearance estimators has been
reported with association of this phenotype to parasite’s chromo-
some 13 [38]. This phenotype includes important contributions
from host [39] as well as parasite factors in assessment (parasite
heritability of approximately 60%), thereby adding to complexi-
ties of understanding underlying mechanisms. The contribution
of parasite dormancy also needs to be ascertained [40].
Almost 2 decades after P-type cation ATPases were hypothe-
sized to be important drug targets in parasites [41], evidence
continues to accumulate in support of SERCAs as targets for
artemisinins [8]. Other calcium pumps [5] are now being ex-
ploited as targets for new classes of drug such as spiroindo-
lones [42], and the assays presented here may also be useful
for their study.
METHODS
Reagents
All reagents were purchased from Sigma Aldrich Chemical Co
except for artemisone (made by R. K. H.) and thaperoxide 22
(made by F. S. and M. A.).
Plasmid Construction
An open reading frame of PfATP6 was codon-optimized for ex-
pression in S. cerevisiae (GeneScript USA Inc). A plasmid con-
taining the wild-type pfatp6 gene regulated by the strong
constitutive glyceraldehyde-3-phosphate dehydrogenase (GPD)
promoter TDH3, was constructed by subcloning the BamHI-
XbaI fragment from commercial vector pcc1 into the expres-
sion vector pUGpd (Ura selectable marker) [43]. Vector
pUGpd is a yeast centromere plasmid containing a yeast cen-
tromere sequence (CEN) and autonomously replicating se-
quence (ARS), which confers mitotic and meiotic stability.
Mutants of PfATP6 were generated using QuikChange Light-
ning Site-Directed Mutagenesis Kit (Stratagene).
Yeast Transformation
The K667 yeast (Saccharomyces cerevisiae) strain (MATa;
pmc1::TRP1; cnb1::LEU2; vcx1Δ; ura3-1) [44] was transformed
with pUGpd-pfatp6, pUGpd-pfatp6-L263E, pUGpd-pfatp6-
Figure 6. Sensitivity of K667::pfatp6 to different concentration of tha-
peroxide 22. A, K667::pfatp6 was diluted to a cell density of 0.1 and inocu-
lated into yeast peptone dextrose (YPD) medium supplemented with 40
mM CaCl2 and thaperoxide 22 as indicated. Yeast cell density was deter-
mined after growth at 30°C for 42 h. Data are mean ± SEM of 6 replicates
(2 independent experiments). Growth in presence of the drug was com-
pared to controls without drug using Student unpaired t test. Inhibition at
100 µM is signiﬁcant (*** P < .0001). The chemical structure of thaperox-
ide 22 is reported. B, BY4741 grown at normal or higher Ca2+ concentra-
tion and K667 expressing pUGpd are not inhibited by thaperoxide 22 (black
bars, no drug; blue bars, 100 µM thaperoxide 22.
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A623E, pUGpd-pfatp6-S769N and pUGpd-pfatp6-A623E/
S769N plasmids, or pUGpd vector only using a Li-acetate
method [45]. Transformants were selected on SD medium
lacking uracil to yield strains K667::pfatp6, K667::pfatp6-L263E,
K667::pfatp6-A623E, K667::pfatp6-S769N, K667::pfatp6-
A623E/S769N, and K667::pUGpd.
Protein Extraction, SDS-PAGE and Western Blotting
SDS gel electrophoresis and Western blots were performed on
yeast total cell lysates prepared from equivalent numbers of log
phase cells grown in SC-ura medium. Cells were pelleted and
lysed by bead beating in SUMEB buffer supplemented with
cOmplete ETDA-free Cocktail tablets protease inhibitor
(Roche). ER-enriched microsomal membranes were prepared
as described elsewhere [46, 47]; 10 µg of protein was used to
load gels. Blots were probed with goat anti-PfATP6 antibody,
followed by mouse rabbit anti-goat immunoglobulin G (IgG)
(H + L)-HRP conjugate secondary (BioRad). Parasite total
protein was obtained from saponin freed 3D7 parasites, treated
with 0.5% Triton X-100 [48].
Indirect Immunoﬂuorescence of Yeast and Parasites
Polyclonal anti-PfATP6 reagent generated in goat from the
peptide CQSSNKKDKSPRGINK (the sequence from Q to K
corresponds to the 574–588 region of PfATP6) was used [11].
Immunoﬂuorescence assay (IFA) on K667::pfatp6 and K667::
pUGpd was with anti-PfATP6 antibody as described else-
where [49]. IFA on P. falciparum 3D7 was performed in solu-
tion, by ﬁxing infected red cells with 4% paraformaldehyde/
0.0075% glutaraldehyde for 30 minutes. Cells were washed in
PBS, permeabilized for 10 minutes (0.1% Triton X-100 in phos-
phate-buffered saline [PBS]) blocked with PBS/3% BSA, and
incubated with anti-PfATP6 antibody for 1 hour and then with
rabbit anti-goat IgG FITC for 30 minutes. Images were taken
using a Nikon TE2000 inverted microscope.
Growth Assays
BY4741 (MATa; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0) yeast and
K667 transformed and untransformed strains were used for
growth assays. For spot assays cells were grown in liquid culture
overnight at 30°C (in synthetic complete [SC] without uracil
and containing 20 g L-1 glucose). After adjusting to OD600 =
0.5, 0.1, 0.02, 0.004, aliquots were inoculated onto agar 2% with
yeast peptone dextrose (YPD) medium and various additions
and incubated at 30°C for 3–5 days. To determine growth rate
in liquid CaCl2 solutions, yeast cultures were inoculated in
YPD medium and grown at 30°C, shaking for 42 hours in 96-
well ﬂat bottomed plates, with absorbance measured at 620 nm.
Drug assays were at speciﬁed concentrations and growth re-
corded at plateau phase (18 hours at basal Ca2+ concentration
and 42 hours at higher Ca2+ concentrations). Concentrations
between 20 and 40 mM calcium were assayed before perform-
ing experiments.
Statistical Analysis
Growth was measured as OD620 or as percentage of control
(growth in YPD medium only) at different conditions and
compared by Student t-test (with 2 alpha considered signiﬁcant
at P < .05). When groups of 3 drug concentrations were com-
pared with growth without drug (Table 1A and Supplementary
Table 1A), then ANOVA with Dunnett test was applied. Possi-
ble outliers were assessed and removed after applying Grubbs
test where indicated in results. All analyses were in GraphPad
(Prism v6.0a).
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